{"id":533260,"date":"2026-06-13T11:23:32","date_gmt":"2026-06-13T11:23:32","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/533260\/"},"modified":"2026-06-13T11:23:32","modified_gmt":"2026-06-13T11:23:32","slug":"tempus-ai-tem-is-one-of-the-best-healthcare-mid-cap-ai-stock-according-to-analysts","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/533260\/","title":{"rendered":"Tempus AI (TEM) Is One Of The Best Healthcare Mid-Cap AI Stock According To Analysts"},"content":{"rendered":"\n

Tempus AI Inc (NASDAQ:TEM<\/b><\/a>) is one of the 12 Best Mid-Cap AI Stocks to Buy According to Analysts<\/b><\/a>. On May 29, Tempus AI Inc (NASDAQ:TEM) announced that it had received FDA approval for a tumor-only indication for its xT CDx sequencing platform. This makes the company the only laboratory to have both tumor-only and tumor-normal comprehensive genomic profiling approvals. This also builds on the company\u2019s solid foundation in leveraging artificial intelligence. The firm sits on over 500 petabytes of data from over 45 million patients.<\/p>\n

\"Tempus Tempus AI Inc (NASDAQ:TEM) is one of the 12 Best Mid-Cap AI Stocks to Buy According to Analysts. <\/p>\n

Tempus AI\u2019s technology now has the ability to identify when a patient receiving a standard drug is expected to do poorly. This will not only help drug companies design smarter clinical trials but also help doctors take better treatment decisions as early as possible. The company\u2019s stock has lost one-fifth of its value in a month, which is understandable, given that most analysts lowered their price targets in May. However, with the success of its sequencing platform, further revisions could come in the short-term, prompting a rally in the stock, which is already up 8% in the last five trading days.<\/p>\n

Tempus AI Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine. It achieves this through its massive libraries of clinical and genomic data. Pharmaceutical companies use their products to improve drug discovery processes while physicians use them to personalize treatments for their patients. The firm is based in Chicago, United States.<\/p>\n

While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you\u2019re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/b><\/a>.<\/p>\n

READ NEXT: <\/b>12 Best Mid-Cap AI Stocks to Buy According to Analysts<\/b><\/a> and <\/b>7 Best Data Centre GPU-as-a-Service Stocks To Buy<\/b><\/a>.<\/b><\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/b><\/a>.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"Tempus AI Inc (NASDAQ:TEM) is one of the 12 Best Mid-Cap AI Stocks to Buy According to Analysts.…\n","protected":false},"author":2,"featured_media":533261,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[275],"tags":[1494,18,208424,135,475,474,19,17,102635,19766,42139],"class_list":["post-533260","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-ai-stock","tag-eire","tag-genomic-data","tag-health","tag-health-care","tag-healthcare","tag-ie","tag-ireland","tag-tem","tag-tempus-ai","tag-tempus-ai-inc"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116742548365188685","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/533260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=533260"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/533260\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/533261"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=533260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=533260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=533260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}